- State-of-the-art site will enable rapid delivery of engineered cell lines 
- Powering ready-to-use edited cell-line portfolio expansion 
- Enable comprehensive customization for research, diagnostic and therapeutic 
development

Today Abcam[http://www.abcamplc.com/] (AIM: ABC; NASDAQ: ABCM), a global 
innovator in life science reagents and tools, announced the opening of a new 
16,000 sq ft purpose-fitted facility in Fremont, CA, which will serve as a 
major new site for its specialist cell engineering team. This state-of-the-art 
facility will enable delivery of engineered cell lines to power expansion of 
the ready-to-use portfolio and facilitate delivery of customization to meet the 
demanding needs of research, diagnostic and therapeutic development.

The move follows Abcam's acquisition of the team and its highly adaptable 
CRISPR-Cas9-based gene editing platform from Applied Stem Cell earlier this 
year. The new facility has received significant investment from the business 
and features an extensive suite of tissue culture labs and is a pivotal part of 
Abcam's ambitious growth plans to expand and cement its position in the edited 
cell line market.

Jac Price, SVP Manufacturing and Supply Chain at Abcam, said: "We are excited 
to be part of the active and growing biotech community in Fremont with our 
newest, customized facility. Our cell engineering team are highly experienced 
and a long-established leader in the edited cell lines market. This facility 
will enable them to further expand and increase the provision of a 
comprehensive cell engineering service for a variety of different life sciences 
applications, at both speed and scale."

This enhanced capability builds upon Abcam's previous acquisition of an 
extensive range of knockout cell lines from 
Edigene[https://www.abcamplc.com/abcam-enters-cell-editing-market-through-acquis
ition-of-edigenes-knock-out-cell-lines-and-lysates-portfolio/] last year. 
Ready-made KO cell lines[https://www.abcam.com/reagents/knockout-cell-lines] 
play a significant role in the study and understanding of biological pathways 
and disease models. Abcam's gene-edited cell line portfolio and engineering 
capability is also supporting the company's award-winning knockout validation 
initiative[https://www.abcam.com/index.html?pageconfig=news&rid=17083], an 
integral part of the organization's ongoing efforts to raise reagent quality 
standards across the industry.

Notes to Editors

About Abcam plc

As a global life sciences company, Abcam identifies, develops, and distributes 
high-quality biological reagents and tools that are crucial to research, drug 
discovery and diagnostics. Working across the industry, the Company supports 
life scientists to achieve their mission, faster. 

Abcam partners with life science organizations to co-create novel binders for 
use in drug discovery, in vitro diagnostics and therapeutics, driven by the 
Company's proprietary discovery platforms and world-leading antibody expertise. 

By constantly innovating its binders and assays, Abcam is helping advance the 
global understanding of biology and causes of disease, which enables new 
treatments and improved health. The Company's pioneering data-sharing approach 
gives scientists increased confidence in their results by providing validation, 
user comments and peer-reviewed citations for its 110,000 products. 

With 13 sites globally, many of Abcam's 1,500-strong team are located in the 
world's leading life science research hubs, complementing a global network of 
services and support. 

To find out more, please visit www.abcam.com and www.abcamplc.com.

Logo - https://mma.prnewswire.com/media/1061261/Abcam_Logo.jpg 

Source: Abcam